STAT+: Amgen’s Repatha linked to fewer heart attacks

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven…

Read the full story at STAT ↗